Table 1. Clinical and radiological characteristics, treatment modalities, and outcomes of patients with PXAs.
| Case | Sex | Age | Initial symptoms | Pre-op KPS | Location | Size (cm)* | Peritumoral edema | Extent of resection | RT (dose, fr) | ChT | Central review | Rec (mo) | F/U (mo) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 7 | NF1 | 100 | Rt. frontal | 4.0 | None | TR | PXA | 158 | Alive | |||
| 2 | F | 13 | Sensory disorder | 100 | Rt. insula | 4.0 | Moderate | STR | SRT (40 Gy, 9 fr) | PXA | 113 | 165 | Alive | |
| 3 | F | 60 | Motor aphasia, visual field constriction | 90 | Lt. temporal | 7.7 | Moderate | STR | PXA | 12 | 72 | Alive | ||
| 4 | M | 30 | Sensory disorder | 100 | Lt. parietal | 7.0 | Moderate | TR | PXA | 59 | Alive | |||
| 5 | M | 65 | Gait disorder | 50 | Lt. temporal | 3.5 | Marked | TR | Local RT (60 Gy, 30 fr) | ACNU IFN TMZ | PXA** | 7 | 28 | Died |
| 6 | F | 59 | Headache, hemiparesis (intratumoral hemorrhage) | 10 | Lt. temporal | 2.0 | None | TR | PXA | 5 | 38 | Died | ||
| 7 | M | 18 | Seizure | 90 | Lt. temporal | 3.5 | Marked | STR | PXA | 37 | 96 | Alive | ||
| 8 | F | 20 | Seizure | 90 | Lt. parietal | 2.3 | Moderate | TR | PXA | 42 | Alive | |||
| 9 | F | 58 | Seizure | 90 | Rt. frontal | 5.5 | Moderate | TR | PXA | 204 | Alive | |||
| 10 | M | 20 | Seizure | 90 | Rt. temporal | 2.0 | Moderate | TR | PXA | 61 | Alive | |||
| 11 | F | 68 | Sensory aphasia | 80 | Lt. parietal | 6.0 | Marked | STR | Local RT (60 Gy, 30 fr) | PXA | 6 | 95 | Alive | |
| 12 | M | 16 | Seizure | 100 | Lt. temporal | 4.0 | Moderate | STR | Local RT (50 Gy, 25 fr) | PXA | 321 | Alive | ||
| 13 | F | 11 | Seizure | 60 | Rt. temporal | 6.0 | Moderate | PR | PCV | PXA | 91 | Alive | ||
| 14 | M | 36 | Headache, nausea | 90 | 4th ventricle | 2.5 | None | TR | PXA | 120 | Alive | |||
| 15 | M | 18 | Seizure | 100 | Rt. temporal | 4.5 | Marked | TR | PXA | 47 | 89 | Alive | ||
| 16 | M | 17 | Seizure | 100 | Rt. parietal | 2.5 | Moderate | TR | PXA | 79 | Alive | |||
| 17 | F | 44 | Seizure | 100 | Rt. temporal | 8.0 | None | TR | PXA | 45 | Alive | |||
| 18 | F | 16 | Headache, nausea, sensory disorder | 90 | Lt. parietal | 7.0 | Moderate | STR | Local RT (60 Gy, 30 fr) Boost SRT (20 Gy, 5 fr) | TMZ | A-PXA | 77 | Alive | |
| 19 | M | 74 | Seizure | 70 | Lt. frontal | 3.5 | Moderate | STR | Local RT (60 Gy, 30 fr) | TMZ | A-PXA | 4 | 9 | Died |
*The longest diameter determined on gadolinium-enhanced T1-weighted magnetic resonance imaging, **local diagnosis was A-PXA.
ACNU: nimustine, ChT: chemotherapy, F: female, fr: fraction, F/U: follow-up, IFN: interferon-beta, KPS: Karnofsky performance status, Lt: left, M: male, mo: months, NF1: neurofibromatosis type 1, PCV: procarbazine, lomustine, and vincristine regimen, PR: partial resection, Pre-op: preoperative, PXAs: pleomorphic xanthoastrocytomas, Rec: recurrence, Rt: right, RT: radiotherapy, SRT: stereotactic radiotherapy, STR: subtotal resection, TMZ: temozolomide, TR: total resection.